CohBar (CohBar) ROCE % : -150.63% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is CohBar ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CohBar's annualized ROCE % for the quarter that ended in Jun. 2023 was -150.63%.

CohBar ROCE % Historical Data

The historical data trend for CohBar's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CohBar ROCE % Chart

CohBar Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-106.32

-75.95

-101.88

-69.32

-59.43

CohBar Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
ROCE %	Get a 7-Day Free Trial															-49.87	-48.49	-89.13	-60.09	-150.63

CohBar ROCE % Calculation

CohBar's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-12.165	/	( ( (27.296 - 1.689)	+	(16.366 - 1.034) )	/ 2 )
	=	-12.165	/	( (25.607	+	15.332)	/ 2 )
	=	-12.165	/	20.4695
	=	-59.43 %

CohBar's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	-17.328	/	( ( (14.402 - 0.899)	+	(12.506 - 3.002) )	/ 2 )
	=	-17.328	/	( ( 13.503	+	9.504 )	/ 2 )
	=	-17.328	/	11.5035
	=	-150.63 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

CohBar (OTCPK:CWBR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CohBar ROCE % Related Terms

Thank you for viewing the detailed overview of CohBar's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CohBar (CohBar) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CohBar Inc (OTCPK:CWBR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1455 Adams Drive, Suite 2050, Menlo Park, CA, USA, 94025

Website

https://www.cohbar.com

CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States.

Executives

Stephanie Tozzo	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Misha Petkevich	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joanne Yun	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joseph J. Sarret	director, officer: Chief Executive Officer	C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carol Nast	director	C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Kenneth C Cundy	officer: Chief Scientific Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jeffrey Francis Biunno	officer: CFO, Treasurer and Secretary	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Steven B Engle	officer: Chief Executive Officer	C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
David Greenwood	director	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Phyllis Gardner	director	618 MIRADA AVENUE, STANFORD CA 94305
Philippe Calais	director	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
John Amatruda	director	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Simon Allen	officer: Chief Executive Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Albion Fitzgerald	director	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jon Leland Stern	director, officer: Chief Executive Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025